NX-1207 is Nymox’s lead drug candidate for the treatment of benign prostatic hyperplasia (BPH). The company believes the drug shows good promise as a potential first-line treatment for BPH.
In two previously completed trials, subjects treated with NX-1207 showed statistically significant overall mean symptom improvement and shrinkage in prostate size. There were no serious adverse events from the drug in these trials. Subjects that were followed for up to two years post-treatment showed even further statistically significant symptom improvement. The analysis of the present on-going phase II trial confirms the drug’s safety in this patient population.
According to Nymox, BPH afflicts approximately half of all men over the age of 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.